CTAGE2/5 Antibody (B-1): sc-365330
- CTAGE2/5 Antibody (B-1) is a mouse monoclonal IgG1 κ CTAGE2/5 antibody provided at 200 µg/ml
- raised against amino acids 141-440 mapping within an internal region of CTAGE2 of human origin
- CTAGE2/5 Antibody (B-1) is recommended for detection of CTAGE2 and CTAGE5 of human origin by WB, IP, IF and ELISA
- Anti-CTAGE2/5 Antibody (B-1) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CTAGE2/5 Antibody (B-1) for WB applications. These reagents are now offered in bundles with CTAGE2/5 Antibody (B-1) (see ordering information below).
CTAGE2/5 Antibody (B-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects CTAGE2/5 of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CTAGE2/5 (B-1) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CTAGE2, a member of the cancer/testis antigen family, plays a significant role in tumor immunology, as CTAGE2 is primarily expressed in the testis and is associated with cutaneous T cell lymphomas (CTCL), a challenging group of malignancies that arise from CD4-T lymphocytes and often present on the skin. CTAGE2 expression in tumors, particularly in CTCL, highlights CTAGE2′s potential as a target for immunotherapy, as CTAGE2 is typically absent in normal tissues, thereby reducing the risk of off-target effects. Additionally, CTAGE2 and CTAGE5, which is also implicated in various tumors, undergo alternative splicing, resulting in multiple isoforms that may have distinct functions or roles in tumor progression. This unique expression pattern and the potential for isoform-specific interactions make anti-CTAGE2/5 antibody (B-1) a valuable tool for researchers studying the mechanisms of CTCL and exploring novel therapeutic strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CTAGE2/5 Antibody (B-1) References:
- Serological detection of cutaneous T-cell lymphoma-associated antigens. | Eichmuller, S., et al. 2001. Proc Natl Acad Sci U S A. 98: 629-34. PMID: 11149944
- The MGEA6 multigene family has an active locus on 14q and at least nine pseudogenes on different chromosomes. | Comtesse, N., et al. 2001. Genomics. 75: 43-8. PMID: 11472066
- MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies. | Comtesse, N., et al. 2002. Oncogene. 21: 239-47. PMID: 11803467
- Towards defining specific antigens for cutaneous lymphomas. | Eichmüller, S. 2002. Onkologie. 25: 448-54. PMID: 12415200
- Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. | Eichmüller, S., et al. 2003. Int J Cancer. 104: 482-7. PMID: 12584747
- cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. | Usener, D., et al. 2003. J Invest Dermatol. 121: 198-206. PMID: 12839582
- The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. | Guinn, BA., et al. 2006. Br J Haematol. 134: 238-9. PMID: 16846483
- Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. | Atanackovic, D., et al. 2006. Cancer Biol Ther. 5: 1218-25. PMID: 16929165
- Concise review: cancer/testis antigens, stem cells, and cancer. | Costa, FF., et al. 2007. Stem Cells. 25: 707-11. PMID: 17138959
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CTAGE2/5 Antibody (B-1) | sc-365330 | 200 µg/ml | $322.00 | |||
CTAGE2/5 Antibody (B-1): m-IgG Fc BP-HRP Bundle | sc-529352 | 200 µg Ab; 10 µg BP | $361.00 | |||
CTAGE2/5 Antibody (B-1): m-IgGκ BP-HRP Bundle | sc-522210 | 200 µg Ab, 40 µg BP | $361.00 | |||
CTAGE2/5 Antibody (B-1): m-IgG1 BP-HRP Bundle | sc-543473 | 200 µg Ab; 20 µg BP | $361.00 | |||
CTAGE2/5 Antibody (B-1) AC | sc-365330 AC | 500 µg/ml, 25% agarose | $424.00 | |||
CTAGE2/5 Antibody (B-1) HRP | sc-365330 HRP | 200 µg/ml | $322.00 | |||
CTAGE2/5 Antibody (B-1) FITC | sc-365330 FITC | 200 µg/ml | $336.00 | |||
CTAGE2/5 Antibody (B-1) PE | sc-365330 PE | 200 µg/ml | $349.00 | |||
CTAGE2/5 Antibody (B-1) Alexa Fluor® 488 | sc-365330 AF488 | 200 µg/ml | $364.00 | |||
CTAGE2/5 Antibody (B-1) Alexa Fluor® 546 | sc-365330 AF546 | 200 µg/ml | $364.00 | |||
CTAGE2/5 Antibody (B-1) Alexa Fluor® 594 | sc-365330 AF594 | 200 µg/ml | $364.00 | |||
CTAGE2/5 Antibody (B-1) Alexa Fluor® 647 | sc-365330 AF647 | 200 µg/ml | $364.00 | |||
CTAGE2/5 Antibody (B-1) Alexa Fluor® 680 | sc-365330 AF680 | 200 µg/ml | $364.00 | |||
CTAGE2/5 Antibody (B-1) Alexa Fluor® 790 | sc-365330 AF790 | 200 µg/ml | $364.00 |